US Bancorp DE Sells 14,890 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

US Bancorp DE lessened its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 17.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 72,046 shares of the medical equipment provider's stock after selling 14,890 shares during the quarter. US Bancorp DE's holdings in Zimmer Biomet were worth $7,777,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD increased its stake in shares of Zimmer Biomet by 12.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider's stock valued at $1,404,638,000 after acquiring an additional 1,215,935 shares during the last quarter. American Century Companies Inc. increased its stake in Zimmer Biomet by 12.6% in the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock valued at $701,521,000 after purchasing an additional 722,041 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Zimmer Biomet by 6.7% in the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider's stock worth $365,163,000 after purchasing an additional 211,637 shares during the period. Van ECK Associates Corp boosted its position in shares of Zimmer Biomet by 5.3% during the second quarter. Van ECK Associates Corp now owns 3,325,598 shares of the medical equipment provider's stock worth $360,927,000 after purchasing an additional 167,038 shares in the last quarter. Finally, Boston Partners grew its holdings in shares of Zimmer Biomet by 26.3% in the 1st quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider's stock valued at $437,413,000 after buying an additional 691,191 shares during the period. Institutional investors own 88.89% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on ZBH. Morgan Stanley dropped their price objective on Zimmer Biomet from $130.00 to $120.00 and set an "equal weight" rating on the stock in a research note on Monday, July 15th. Truist Financial raised their price target on Zimmer Biomet from $112.00 to $117.00 and gave the stock a "hold" rating in a research report on Friday. JPMorgan Chase & Co. decreased their price objective on Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating for the company in a research report on Monday, September 16th. Oppenheimer dropped their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating on the stock in a report on Tuesday, October 15th. Finally, Evercore ISI reduced their price target on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating for the company in a report on Tuesday, October 1st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $124.11.

Zimmer Biomet Stock Performance

NYSE ZBH traded up $1.14 during trading on Monday, reaching $108.41. The company's stock had a trading volume of 1,427,645 shares, compared to its average volume of 1,491,139. The firm has a 50 day moving average price of $106.96 and a 200 day moving average price of $110.73. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90. The firm has a market capitalization of $21.58 billion, a price-to-earnings ratio of 20.46, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.63 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.74. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.65 earnings per share. As a group, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were paid a $0.24 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.89%. Zimmer Biomet's payout ratio is 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.